NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $16.60.

A number of brokerages have commented on NPCE. Zacks Research cut shares of NeuroPace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroPace in a research note on Saturday, September 27th. Finally, Wells Fargo & Company cut their target price on NeuroPace from $17.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Two Sigma Investments LP bought a new position in NeuroPace during the 4th quarter valued at about $293,000. First Light Asset Management LLC bought a new position in shares of NeuroPace in the first quarter valued at approximately $19,468,000. HighMark Wealth Management LLC raised its stake in shares of NeuroPace by 2,000.0% in the second quarter. HighMark Wealth Management LLC now owns 63,000 shares of the company’s stock valued at $702,000 after acquiring an additional 60,000 shares during the last quarter. Palumbo Wealth Management LLC raised its stake in shares of NeuroPace by 300.4% in the first quarter. Palumbo Wealth Management LLC now owns 46,111 shares of the company’s stock valued at $567,000 after acquiring an additional 34,594 shares during the last quarter. Finally, Ghisallo Capital Management LLC bought a new position in shares of NeuroPace in the first quarter valued at approximately $2,458,000. 78.83% of the stock is owned by institutional investors.

NeuroPace Price Performance

Shares of NPCE stock opened at $10.65 on Wednesday. The stock has a 50 day moving average of $9.48 and a two-hundred day moving average of $11.01. The company has a current ratio of 5.47, a quick ratio of 4.51 and a debt-to-equity ratio of 3.02. NeuroPace has a 12 month low of $5.45 and a 12 month high of $18.98. The company has a market capitalization of $352.30 million, a P/E ratio of -12.68 and a beta of 1.91.

NeuroPace (NASDAQ:NPCE) last issued its earnings results on Tuesday, August 12th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $23.52 million during the quarter, compared to the consensus estimate of $23.08 million. NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%. NeuroPace has set its FY 2025 guidance at EPS. As a group, equities analysts expect that NeuroPace will post -1 EPS for the current year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.